A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 245
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : MAOI
Long Form : monoamine oxidase inhibitor
No. Year Title Co-occurring Abbreviation
2019 Depression increases the risk of inflammatory bowel disease, which may be mitigated by the use of antidepressants in the treatment of depression. CD, SNRI, SSRI, TCA, UC
2019 Effects of Epacadostat on Brain Extracellular Fluid Concentrations of Serotonin-an Intracerebral Microdialysis Study in Sprague-Dawley Rats. ECF, EPAC, IDO1, SS
2019 Relative effectiveness of tricyclic antidepressant versus monoamine oxidase inhibitor monotherapy for treatment-resistant depression. TCA, TRD
2019 Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. CNS, NPSs, SS, TPH
2019 Syrian rue seeds interacted with acacia tree bark in an herbal stew resulted in N,N-dimethyltryptamine poisoning. DMT
2018 Hybrid caffeic acid derivatives as monoamine oxidases inhibitors: synthesis, radical scavenging activity, molecular docking studies and in silico ADMET analysis. ---
2018 Khat: A Substance of Growing Abuse with Adverse Drug Interaction Risks. CNS
2018 Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome. MB, SS
2018 Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. BMI, Css
10  2017 A rapid and simple method for the determination of psychoactive alkaloids by CE-UV: application to Peganum Harmala seed infusions. ---
11  2017 Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). ADs, MDD, ORs, SNRI, SSRI, TCA
12  2017 Augmentation of phenelzine with aripiprazole and quetiapine in a treatment-resistant patient with psychotic unipolar depression: case report and literature review. SGAs
13  2017 Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015. AAPCC, DMT, NPDS
14  2017 Chronic CB1 cannabinoid receptor antagonism persistently increases dendritic spine densities in brain regions important to zebra finch vocal learning and production in an antidepressant-sensitive manner. ---
15  2017 Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. DA, NMA, PD, SNRI, SSRI, SUCRA, TCA
16  2017 Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents: A Retrospective Study Utilizing Two Large US Claims Databases. SAs, SS, VHA
17  2017 Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire. DA, HY, PD, UPDRS
18  2016 "Ping-pong gaze" secondary to monoamine oxidase inhibitor overdose. PPG
19  2016 Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize the thermoregulatory effects of serotonergic drugs in mice. 5-MeODMT, PK/PD
20  2016 Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms. 5-MeODMT, AUEC, IAA
21  2016 [Antidepressant and tolerance: Determinants and management of major side effects]. SNRI, SSRI, TCA
22  2016 [Combining a classic monoamine oxidase inhibitor with a tricyclic antidepressant in therapy-resistant depression: a case report and literature review]. TCA
23  2015 Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO-B Inhibitors. ---
24  2014 Effects of combined MAO-B inhibitors and levodopa vs. monotherapy in Parkinson's disease. CDS, DA, PD
25  2014 EMSAM (deprenyl patch): how a promising antidepressant was underutilized. ---
26  2014 New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. ---
27  2014 Soma, food of the immortals according to the Bower Manuscript (Kashmir, 6th century A.D.). ---
28  2013 Harmine augments electrically evoked dopamine efflux in the nucleus accumbens shell. DA, MAOA
29  2013 Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. AD, MTDL
30  2013 Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy. ---
31  2013 Xanthoangelol and 4-Hydroxyderricin Are the Major Active Principles of the Inhibitory Activities against Monoamine Oxidases on Angelica keiskei K. A. keiskei K, DBH
32  2013 [Phenelzine: legacy or current psychiatric practice?]. ---
33  2012 Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment. DMT, DYRK1A
34  2012 Influence of chronic administration of antidepressant drugs on mRNA for galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-body regions in rat brain. AD, GAL, LC, NE, SSRI, TH, VTA
35  2012 Levels of biogenic amines in retail market fermented meat products. BA, OPA
36  2012 Prediction of longer-term outcome of treatment-resistant depression in tertiary care. ---
37  2012 The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. ABC, FLC, HTS, MFS, PCL, R6G
38  2012 The predictive validity of atypical neurovegetative depressive symptoms identified by the first principal component in the DUAG trial of moclobemide versus clomipramine. DUAG, PCA, QSAD
39  2011 CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. ---
40  2011 MAO-inhibitors in Parkinson's Disease. L-dopa, PD
41  2011 [Switch antidepressants: when? How? Why?]. ---
42  2010 An algorithm for the pharmacological treatment of depression. AD
43  2010 Changing epidemiology of intentional antidepressant drug overdose in Victoria, Australia. OD, SSRIs, TCAs, VEMD, VPIC
44  2010 Phenelzine-induced myocardial injury: a case report. ---
45  2010 Quantification of antidepressants using gas chromatography-mass spectrometry. GC/MS, LLE, SNRI, SSRI, TCA
46  2009 A pragmatic approach to biochemical systems theory applied to an alpha-synuclein-based model of Parkinson's disease. BST, PD
47  2009 Atypical depression: retrospective self-reporting of treatment effectiveness. ---
48  2009 Social anxiety disorder: epidemiology, biology and treatment. SAD, SNRI, SSRI
49  2008 Differential effects of imipramine and phenelzine on corticosteroid receptor gene expression in mouse brain: potential relevance to antidepressant response. GR, HPA, MR, TCA
50  2008 Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. ECS, SSRI, TCA
51  2008 Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal-induced place aversion. ---
52  2008 Neurological complications of psychiatric drugs: clinical features and management. EPS, NMS, SSRI, TCAs
53  2007 A history of the concept of atypical depression. ---
54  2007 Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. MAOA, SSRI, ST
55  2007 Pharmacological causes of hyperprolactinemia. SSRI
56  2007 Receptor mediation of exaggerated responses to serotonin-enhancing drugs in serotonin transporter (SERT)-deficient mice. 5-HTP, SERT
57  2007 Reversal of learned helplessness by selective serotonin reuptake inhibitors in rats is not dependent on 5-HT availability. LH, LLR, PCPA, SSRIs
58  2007 Treating depression with atypical features. SSRIs, TCAs
59  2007 Treating DSM-IV depression with atypical features. TCAs
60  2006 Nitric oxide synthesis is required for exercise-induced increases in hippocampal BDNF and phosphatidylinositol 3' kinase expression. L-NAME, NO, PI3K
61  2006 Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. ADHD
62  2006 Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. ---
63  2006 Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. MDD, STS
64  2005 Chronic treatment with the monoamine oxidase inhibitor phenelzine increases hypothalamic-pituitary-adrenocortical activity in male C57BL/6 mice: relevance to atypical depression. ---
65  2005 Effect of I-deprenyl and gliclazide on oxidant stress/antioxidant status and dna damage in a diabetic rat model. EL, MDA, OAD, SOD, TAS
66  2005 Heteroarylisopropylamines as MAO inhibitors. ---
67  2005 Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. SRIs
68  2005 Parkinson's disease. Diagnosis and the initiation of therapy. CBD, MSA, PD, PSP, VP
69  2005 Screening antidepressants in the chick separation-stress paradigm. NRI, SSRI, TCA
70  2004 Clinical applications of MAO-inhibitors. SSRI's
71  2004 Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. ---
72  2004 Hallucinogens and dissociative agents naturally growing in the United States. NAC, UDV
73  2003 Clorgyline-induced switch from locomotion to mouthing in sensitization to the dopamine D2/D3 agonist quinpirole in rats: role of sigma and imidazoline I2 receptors. MQB
74  2003 Linezolid: new preparation. In severe gram-positive infections. ---
75  2003 Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. ADHD
76  2003 Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. ---
77  2003 [Elderly patients, classical monoamine oxidase inhibitors and intercurrent somatic diseases]. ---
78  2002 5-Hydroxytryptophan (5-HTP) uptake and decarboxylation in the kitten brain. 5-HTP, DA, IR, NA, TP, VLPH
79  2002 Different effects of phenelzine treatment on EEG topography in waking and sleep in depressed patients. REM
80  2002 Effects of the antidepressant/antipanic drug phenelzine and its putative metabolite phenylethylidenehydrazine on extracellular gamma-aminobutyric acid levels in the striatum. GABA, PEH, PLZ
81  2002 Interactions between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. ECT, TCAs
82  2002 Monoamine oxidase inhibitor-induced blockade of locomotor sensitization to quinpirole: role of striatal dopamine uptake inhibition. ---
83  2002 Serotonin syndrome due to an overdose of moclobemide? ---
84  2002 World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. SSRIs, TCAs, WFSBP
85  2001 Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. SSRI
86  2001 Drug interactions with selective serotonin reuptake inhibitors, especially with other psychotropics. SSRIs
87  2001 Effect of chronic phenelzine treatment on REM sleep: report of three patients. EEG
88  2001 Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. BP, OTC
89  2001 Pharmacotherapy of depression: a historical analysis. ---
90  2001 Pharmanopo-psychonautics: human intranasal, sublingual, intrarectal, pulmonary and oral pharmacology of bufotenine. ---
91  2001 Pharmepena-Psychonautics: Human intranasal, sublingual and oral pharmacology of 5-methoxy-N,N-dimethyl-tryptamine. ---
92  2000 A comparison of drugs versus placebo for the treatment of dysthymia. CI, NNH, NNT, RR, SSRI
93  2000 A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats. MQB
94  2000 Anaphylaxis and monoamine oxidase inhibitors--the use of adrenaline. ---
95  2000 Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. ADs, FPT, SSRIs
96  2000 Drugs versus placebo for dysthymia. CI, NNH, NNT, RR, SSRI
97  2000 Safe use of remifentanil in a patient treated with the monoamine oxidase inhibitor phenelzine. ---
98  2000 Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. SNRI, SSRIs, TCA
99  1999 5-HT agonist-induced phase-advances of the circadian pacemaker are diminished by chronic antidepressant drug treatment. AD, VEH
100  1999 Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. SSRI, TCA